Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (November 2012)
25 slides from Elron Ventures's investor presentation, Nov 19, 2012
Slide 1: November 2012
November 2012
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the fe
Slide 3: Quarter highlights
§ GIVEN IMAGING: Net income increased 58% to $6.0 million, compared to $3.8 million in the same quarter of last year. § GIVEN IMAGING plans to submit the PillCam COLON 2 capsule for FDA clearance by the end of the year. § RDC, Elron’s and Rafael’s jointly held subsidiary, signed a term sheet for the
Slide 4: Major exits
Sale of company to Alvarion for $30m Sale of company to Wave Systems Corp for $13m Sale of assets to Microsoft for $35m Sale of holdings to Discount Investment Corp and Clal Industries and Investments for $60m Sale of company to Enablence for $50m Sale of company to Roche for $179m June 2009 October
Slide 5: Elron > Med Tech
ELRON > MED TECH
Slide 6: Group companies / Med-Tech
GROUP COMPANIES / MED-TECH: ELRON > MED TECH
Slide 7: The way we work > Active management
THE WAY WE WORK > ACTIVE MANAGEMENT § FOCUS on investments in which we can exert significant influence and take an active role in their management. § LEVERAGE KNOW-HOW, EXPERTISE, AND NETWORK of global partners to identify and realize opportunities. § SEEK A LEAD SHAREHOLDER POSITION in core assets
Slide 8: Main investments 2011-2012
MAIN INVESTMENTS 2011 -2012 >
Slide 9: My d y sect RONte
a My d y sect RONte \ TRIES LTD, | INDES
Slide 10: BrainsGate overview
§ Elron’s holding: 30% § Device for treating ischemic stroke in 24 hour window post symptom onset, as opposed to treatment with the tPA protein which is only approved for use during a window that lasts just several hours § Electrical stimulation of SPG (a nerve center located behind the nasal cavity
Slide 11: Stroke statistics
Sources: World Health Organization website: http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf. American Heart Association: Heart Disease and Stroke Statistics - 2010 Update.
Slide 12: BrainsGate clinical trial
§ BrainsGate conducted a clinical trial on approximately 300 patients, whose results strengthen the assessment that BrainsGate’s treatment has a considerable clinical effect, which is stronger than the effect found in current treatments. § Since June 2011, BrainsGate has been enrolling patients in a
Slide 13: Pocared overview
§ Innovative real-time and automated system for infectious diseases diagnosis using optical technology § The system’s first application is diagnosis of urinary tract infection (UTI) § The system is designed for use by major microbiological laboratories and hospitals, as an alternative to the current
Slide 14: Diagnostics market sources
Sources: Venture Planning 2006 Automated Microbiology Report. Interviews conducted by Pocared with leading microbiology laboratories managers. Frost & Sullivan - U.S. Diagnostics Markets, December 2006, European IVD Market, September 2006’ Frost & Sullivan Global IVD Market Outlook, May 2005
Slide 15: Pocared FDA trial and holding
§ Sample collection for the company’s FDA trial will begin after it completes suiting the sample processing procedure to the system’s diagnostic method. § During the third quarter of 2011, Elron increased its holding in the company after purchasing another shareholder’s shares and completing another
Slide 16: Elron and Rafael strategic partnership (RDC)
Strategic partnership between Elron and Rafael, through a jointly owned subsidiary, that has access to state of the art technologies developed by Rafael and exclusive rights to commercialize them Rafael - Advanced Defense Systems develops & manufactures state of the art armaments for the Israel Defe
Slide 17: RDC investment: coronary imaging system
§ An investment through RDC, Elron’s and Rafael’s jointly held company. § RDC’s holding: 87% § The company developed an online image processing system designed to optimize and facilitate coronary catheterizations, from device positioning, to deployment, and post-deployment analysis. § FDA-cleared an
Slide 18: SmartWave defibrillator
§ The defibrillator immediately and automatically detects and terminates atrial fibrillation (AF) episodes (a type of irregular heartbeat), without the need for hospitalization. § The device delivers electrical pulses to restore the heart’s normal rhythm (electrical cardioversion). § RDC’s holding:
Slide 19: Heart disease statistics source
American Heart Association: Heart Disease and Stroke Statistics - 2012 Update
Slide 20: CartiHeal
§ Develops implants for repairing cartilage and osteochondral defects in loadbearing joints, such as the knee and ankle. § CartiHeal's first product is indicated for treatment of cartilage defects in the knee. § Pre-clinical and clinical trials on the first product have demonstrated the regeneration
Slide 21: Market sources
BioMedGPS, 2012; Medtech Insight, January 2011
Slide 22: Given Imaging update
§ The company recently had a meeting with the FDA to discuss the process for market clearance of the PillCam COLON 2 capsule for the visualization of the colon. § Based on the meeting, the company plans to submit this product for FDA clearance by the end of the year under the direct de novo route. §
Slide 23: Elron financial data
Effective Public Holdings (Market value as of November 11, 2012) ($m) Given Imaging 154.8 Other holdings 0.3 Total Public Holdings 155.1 Private Holdings (Book value as of September 30, 2012) Pocared 2.8 BrainsGate 3.4 Other holdings 1 30.2 Total Private Holdings 36.4 Financial Assets, net (as of Se
Slide 24: About Elron
§ Elron was established in 1962 by Uzia Galil in order to develop the Israeli hi-tech industry. § In 1975, the company listed on the Tel Aviv Stock Exchange under the symbol ELRN. § Over the past five decades, the company has been instrumental in building groundbreaking Israeli hi-tech companies. §
Slide 25: info@elron.com
info@elron.com
Elron Electronic Industries — Investor Presentation (November 2012) on 6ix